SRZN News & Events

Andrew Maleki has joined the Surrozen management team as CFO. Maleki brings more than a decade of experience in the biotech industry spanning corporate strategy, business development and operational leadership, including playing a key role in raising over $500M in capital. Most recently, he led corporate development and program leadership at Lassen Therapeutics, where he helped shape portfolio strategy and business development efforts.

Surrozen announced the issuance of U.S. Patent No. 12,297,278. Surrozen has six issued U.S. patents, 10 patents issued in other countries, 11 patent families pending in the U.S. and other countries, five patent families pending in the U.S. only, two pending PCT applications, and four patent families with pending U.S. provisional applications, and has two in-licensed patent families related to the Wnt pathway and its modulation. In May 2025, Surrozen was granted U.S. Patent No. 12,297,278 related to its SWAPTM technology. The patent covers tetravalent, multi-specific Wnt surrogates comprised of: two Frizzled binding regions that specifically bind to two Fzd receptors, wherein each of the two Fzd binding regions comprises an antibody or antigen-binding fragment of the antibody; and two LRP5/6 binding regions that specifically bind to a Low-density lipoprotein receptor-related protein 5 and/or a LDL receptor-related protein 6, wherein each of the two LRP5/6 binding regions comprises an antibody or antigen-binding fragment of the antibody, and wherein each of the two LRP5/6 binding regions is fused to one of the two Fzd binding regions via a linker moiety.